cas 836-59-9|| where to buy 4-(2-(4-Bromophenoxy)ethyl)morpholine

Nom du produit:4-(2-(4-Bromophenoxy)ethyl)morpholine

IUPAC Name:4-[2-(4-bromophenoxy)ethyl]morpholine

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM279800-5g	in stock	ƅƏƅ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 836-59-9 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:836-59-9; Formule moléculaire:C12H16BrNO2; Point de fusion:-; Code SMILES:BrC1=CC=C(OCCN2CCOCC2)C=C1; Densité:

: Numéro de catalogue:CM279800; Poids moléculaire:286.17; Point d'ébullition:; N° Mdl:MFCD01308572; Stockage:

: Morpholines; Morpholine contains secondary amine groups and has all the typical reactive characteristics of secondary amine groups. It can react with inorganic acids to form salts, and react with organic acids to form salts or amides, which can be subjected to alkylation reaction, and can also be reacted with ethylene oxide, ketone or Willgerodt reaction. Morpholine is a six-membered ring containing oxygen and nitrogen, and its alkalinity is much lower than that of its parent piperidine. The marketed morpholine drugs are mainly distributed in the fields of tumors, cardiovascular and cerebrovascular diseases, respiratory system diseases, digestive system diseases, infectious diseases and mental disorders.; morpholine price; if you are interested in morpholine price, please feel free to contact us. More information of our products will be forwarded to you upon receipt of your specific inquiry.

: Tirbanibulin; Actinic keratosis (AK) is a chronic disease resulting from deleterious effects of long-term, cumulative, epidermal exposure to ultraviolet (UV) light.
Tirbanibulin is a synthetic, first-in-class, potent anti-proliferative agent that has shown antiproliferative and antitumoral effects in vitro and in vivo by inducing cell cycle arrest and ultimately apoptotic cell death. These effects have been attributed to the ability of tirbanibulin to reversibly bind to the colchicine-binding site on b-tubulin and inhibit tubulin microfilament polymerization.
The U.S. actinic keratosis treatment market size was valued at USD 2.94 billion in 2023 and is projected to reach USD 3.96 billion by 2033, growing at a CAGR of 3.04% from 2024 to 2033.